Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Total Non-Current Liabilities: 2023-2024

Historic Total Non-Current Liabilities for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $218,000.

  • Zenas BioPharma's Total Non-Current Liabilities was N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year change of. This contributed to the annual value of $218,000 for FY2024, which is 99.07% down from last year.
  • As of FY2024, Zenas BioPharma's Total Non-Current Liabilities stood at $218,000, which was down 99.07% from $23.5 million recorded in FY2023.
  • Zenas BioPharma's Total Non-Current Liabilities' 5-year high stood at $23.5 million during FY2023, with a 5-year trough of $218,000 in FY2024.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $11.9 million (2023), whereas its average is $11.9 million.
  • Data for Zenas BioPharma's Total Non-Current Liabilities shows a maximum YoY crashed of 99.07% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Zenas BioPharma's Total Non-Current Liabilities stood at $23.5 million in 2023, then tumbled by 99.07% to $218,000 in 2024.